Telo Genomics Corp. (TDSGF)

Telo Genomics Cash Flow Statement

Financials in millions CAD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	-2.71	-2.82	-2.11	-1.07	-1.24
Depreciation & Amortization	0.04	0.03	0.06	0.06	0.06
Loss (Gain) From Sale of Assets	0	-	-	-	-
Stock-Based Compensation	0.06	0.16	0.15	0.14	0.36
Other Operating Activities	-0.01	-	-	-0.19	-0.1
Change in Accounts Receivable	0.03	-0.03	0.06	-0.05	-0.01
Change in Accounts Payable	0.11	0.07	0.08	-0.04	-0.15
Change in Other Net Operating Assets	0.01	-0.05	-0.03	0.04	-0.04
Operating Cash Flow	-2.46	-2.63	-1.79	-1.1	-1.12
Capital Expenditures	-0.01	-0.07	-0.03	-0.01	-
Sale (Purchase) of Intangibles	-	-	-	-	-0.01
Investing Cash Flow	-0.01	-0.07	-0.03	-0.01	-0.01
Short-Term Debt Issued	-	-	-	-	0.35
Long-Term Debt Issued	-	-	-	-	0.04
Total Debt Issued	-	-	-	-	0.39
Short-Term Debt Repaid	-	-	-	-0.02	-
Long-Term Debt Repaid	-0.02	-0.01	-	-	-
Total Debt Repaid	-0.02	-0.01	-	-0.02	-
Net Debt Issued (Repaid)	-0.02	-0.01	-	-0.02	0.39
Issuance of Common Stock	0.65	2.89	0.89	3.99	1.75
Other Financing Activities	-0.04	-0.21	-0.02	-0.15	-0.11
Financing Cash Flow	0.59	2.68	0.88	3.83	2.03
Net Cash Flow	-1.88	-0.02	-0.94	2.72	0.9
Free Cash Flow	-2.46	-2.7	-1.82	-1.11	-1.12
Free Cash Flow Per Share	-0.04	-0.04	-0.03	-0.02	-0.04
Levered Free Cash Flow	-1.46	-1.62	-1.03	-0.84	-1.15
Unlevered Free Cash Flow	-1.46	-1.62	-1.03	-0.84	-1.13
Change in Net Working Capital	-0.14	-0.01	-0.11	0.25	0.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.